Antihistamines and Myelin Repair

A 2017 study published in The Lancet aimed to analyze the efficacy and safety of clemastine fumarate, an antihistamine, as a treatment for patients with multiple sclerosis.

Study: Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial 

This study showed that a small group of patients suffering with multiple sclerosis, who took antihistamines, experienced modest repair to myelin. These findings suggest that myelin repair can be achieved, even following prolonged damage.

This is really significant because none of the disease modifying drugs have been shown to be associated with myelin repair – this is the first drug associated with any myelin repair.

Clemastine fumarate is an over-the-counter allergy medication, however doses in this trial exceeded the recommended maximum for over-the-counter use.

“This is a significant step forward in one of many different approaches being taken to find a way to repair the nervous system damage caused by MS,” said Bruce Bebo, PhD, Executive Vice President, Research at the National MS Society. “Research to restore function to people with MS is a very high priority.”

I created a video to share the findings of this exciting study update, and to discuss the possible benefits of using antihistamines to support the recovery from MS.

Author Pam Bartha

Clinically diagnosed with multiple sclerosis at the age of 28, Pam chose an alternative approach to recovery. Now decades later and still symptom free, she coaches others on how to treat the root cause of chronic disease, using a holistic approach. She can teach you how, too.

Pam is the author of Become a Wellness Champion and founder of Live Disease Free. She is a wellness expert, coach and speaker.

The Live Disease Free Academy has helped hundreds of Wellness Champions in over 15 countries take charge of their health and experience profound improvements in their life.

Leave a Reply

Your email address will not be published. Required fields are marked *